Generalized in vitro-in vivo relationship (IVIVR) model based on artificial neural networks

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 223-232

  Mendyk, Aleksander ^a   Tuszyński, Paweł K ^a   Polak, Sebastian ^a   Jachowicz, Renata ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Artificial neural networks; Bioavailability; Correlation; In vitro in vivo; Relationship; Soft computing

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; DANAZOL; DICLOFENAC; DILTIAZEM; EXCIPIENT; GRISEOFULVIN; IBUPROFEN; KETOPROFEN; LEVOSIMENDAN; METOPROLOL; POLYMER; PROPRANOLOL; RITONAVIR; THEOPHYLLINE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; DATA ANALYSIS SOFTWARE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; FUZZY SYSTEM; IN VITRO IN VIVO RELATIONSHIP; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

ARTIFICIAL NEURAL NETWORKS; BIOAVAILABILITY; CORRELATION; IN VITRO-IN VIVO; RELATIONSHIP; SOFT COMPUTING;

BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; EXCIPIENTS; HUMANS; MODELS, THEORETICAL; NEURAL NETWORKS (COMPUTER); PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 84875673211     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41401     Document Type: Article

References (44)

1. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry SUPAC-MR: modified release solid oral dosage forms scale-up and postapproval changes; chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070640.pdf. Accessed February 17, 2013.
2. Emami J. In vitro-in vivo correlation: from theory to applications. J Pharm Sci. 2006;9:169-189.
3. Polli JE. IVIVR versus IVIVC. Available from: http://www.dissolutiontech.com/DTresour/800Articles/800_art1.html. Accessed February 17, 2013.
4. Zurada JM. Introduction to Artificial Neural Systems. St Paul, MN: West Publishing Company; 1992.
5. Chen Y, McCall TW, Baichwal AR, Meyer MC. The application of an artificial neural network and pharmacokinetic simulations in the design of controlled-release dosage forms. J Control Release. 1999;59:33-41.
6. Bourquin J, Shmidli H, van Hoogevest P, Leuenberger H. Advantages of artificial neural networks (ANNs) as alternative modeling technique for data sets showing non-linear relationship using data from a galenical study on a solid dosage form. Eur J Pharm Sci. 1998;7:5-16.
7. Mendyk A, Jachowicz R. Neural network as a decision support system in the development of pharmaceutical formulation-focus on solid dispersions. Expert Syst Appl. 2005;28:285-294.
8. Mitra A, Wu Y. Use of in vitro-in vivo correlation (IVIVC) to facilitate the development of polymer-based controlled release injectable formulations. Recent Pat Drug Deliv Formul. 2010;4:94-104.
9. Türkoǧlu M, Özarslan R, Sakr A. Artificial neural network analysis of a direct compression tabletting study. Eur J Pharm Biopharm. 1995;41: 315-322.
10. Rocksloh K, Rapp FR, Abed Abu S, etal. Optimization of crushing strength and disintegration time of a high-dose plant extract tablet by neural networks. Drug Dev Ind Pharm. 1999;25:1015-1025.
11. Belic A, Skrjanc I, Bozic DZ, Karba R, Vrecer F. Minimisation of the capping tendency by tableting process optimisation with the application of artificial neural networks and fuzzy models. Eur J Pharm Biopharm. 2009;73:172-178.
12. Brier ME, Zurada JM. Neural network predicted peak and trough gentamicin concentrations. Pharm Res. 1995;12:406-412.
13. Chow HH, Tolle KM, Roe DJ, Elsberry V, Chen H. Application of neural networks to population pharmacokinetic data analysis. J Pharm Sci. 1997;86:840-845.
14. Opara J, Primozic S, Cvelbar P. Prediction of pharmacokinetic parameters and the assessment of their variability in bioequivalence studies by artificial neural networks. Pharm Res. 1999;16:944-948.
15. Yamamura S, Kawada K, Takehira R, etal. Artificial neural network modeling to predict the plasma concentration of aminoglycosides in burn patients. Biomed Pharmacother. 2004;58:239-244.
16. Agatonovic-Kustrin S, Turner JV, Glass BD. Quantitative structure-retention-pharmacokinetic relationship studies. Drug Metab Lett. 2008;2:130-137.
17. Poynton MR, Choi BM, Kim YM, etal. Machine learning methods applied to pharmacokinetic modelling of remifentanil in healthy volunteers: a multi-method comparison. J Int Med Res. 2009;37: 1680-1691.
18. De Matas M, Shao Q, Silkstone VL, Chrystyn H. Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks. J Pharm Sci. 2007;96:3293-3303.
19. Dowell J, Hussain A, Devane J, Young D. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. J Pharm Sci. 1999;88:154-160.
20. Parojčić J, Ibrić S, Djurić Z, Jovanović M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur J Pharm Sci. 2007;30:264-272.
21. Fatouros DG, Nielsen FS, Douroumis D, Hadjileontiadis LJ, Mullertz A. In vitro-in vivo correlations of self-emulsifying drug delivery systems combining the dynamic lipolysis model and neuro-fuzzy networks. Eur J Pharm Biopharm. 2008;69:887-898.
22. ChemAxon. [homepage on the Internet]. ChemAxon company. Available from: http://www.chemaxon.com. Accessed December 6, 2012.
23. Bilski J. The back-propagation learning with logarithmic transfer function. Abstract presented at the Fifth Conference Neural Networks and Soft Computing, June 6-10, 2000, Zakopane, Poland.
24. Mendyk A, Jachowicz R. Unified methodology of neural analysis in decision support systems built for pharmaceutical technology. Expert Syst Appl. 2007;32:1124-1131.
25. Z. urada JM, Malinowski A, Usui S. Perturbation method for deleting redundant inputs of perceptron networks. Neurocomputing. 1997;14: 177-193.
26. g3data. [homepage on the Internet]. g3data software for extracting data from graphs. Available from: http://www.frantz.fi/software/g3data.php. Accessed December 6, 2012.
27. Kortejärvi H, Malkki J, Marvola M, etal. Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series. J Pharm Sci. 2006;95:1595-1605.
28. Kortejärvi H, Mikkola J, Bäckman M, Antila S, Marvola M. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. Int J Pharm. 2002;241:87-95.
29. Rossi RC, Dias CL, Donato EM, etal. Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int J Pharm. 2007;338:119-124.
30. Sunesen VH, Vedelsdal R, Kristensen HG, Christrup L, Müllertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005;24:297-303.
31. Eddington N, Marroum P, Uppoor R, Hussain A, Augsburger L. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. Pharm Res. 1998;15:466-473.
32. Eddington N, Rekhi G, Lesko L, Augsburger L. Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. AAPS Pharm Sci Tech. 2000;1:a14.
33. Rekhi GS, Eddington ND, Fossler MJ, etal. Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharm Dev Tech Technol. 1997;2:11-24.
34. Sirisuth N, Eddington N. The influence of first pass metabolism on the development and validation of an IVIVC for metoprolol extended release tablets. Eur J Pharm Biopharm. 2002;53:301-309.
35. Ahmed IS, Aboul-Einien MH. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur J Pharm Sci. 2007;32:58-68.
36. Korhonen O, Kanerva H, Vidgren M, Urtti A, Ketolainen J. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. J Control Release. 2004;95:515-520.
37. Mahaguna V, Talbert R, Peters J, etal. Influence of hydroxypropyl methylcellulose polymer on in vitro and in vivo performance of controlled release tablets containing alprazolam. Eur J Pharm Biopharm. 2003;56:461-468.
38. Roda A, Sabatini L, Mirasoli M, Baraldini M, Roda E. Bioavailability of a new ketoprofen formulation for once-daily oral administration. Int J Pharm. 2002;241:165-172.
39. Rani M, Mishra B. Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS Pharm Sci Tech. 2004;5:153-159.
40. Jung H, Milán R, Girard M, León F, Montoya M. Bioequivalence study of carbamazepine tablets, in vitro/in vivo correlation. Int J Pharm. 1997;152:37-44.
41. Honkanen O, Pia L, Janne M, etal. Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations. Eur J Pharm Sci. 2002;15:479-488.
42. Nykänen P, Lempää S, Aaltonen M, etal. Citric acid as excipient in multiple-unit enteric-coated tablets for targeting drugs on the colon. Int J Pharm. 2001;229:155-162.
43. Hayashi T, Kanbe H, Okada M, etal. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets. Int J Pharm. 2007;341:105-113.
44. Zaid AN, Natour S, Qaddomi A, Abu Ghoush A. Formulation and in vitro and in vivo evaluation of film coated montelukast sodium tablets using Opadry yellow 20A82938 on an industrial scale. Drug Des Devel Ther. 2013;7:25-31.